The content on this site is intended for healthcare professionals only
Dr Heather McArthur speaks to ecancer about the final analysis of the ALEXANDRA/IMpassion030 phase 3 trial. The ALEXANDRA/IMpassion030 trial was conducted to study the effect of atezolizumab, a cancer drug, on patients suffering from triple-negative breast cancer.
The trial included patients from 31 countries who had undergone surgery to remove their cancer.
Half of the patients were randomly assigned to be treated with chemotherapy along with atezolizumab, while the other half received only chemotherapy.
The researchers observed that there was no significant improvement in the survival rate and cancer-free duration of patients who were treated with atezolizumab after surgery compared to those who were not treated with the drug.
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Comment: EBCC 2024 highlights
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
ESMO 2023: Highlights and analysis
Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients
The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer
Overview of the management of HER2-low breast cancer patients
